CAR T 是一种药物还是一种治疗途径？复发难治弥漫大B细胞淋巴瘤CAR-T细胞疗法真实世界研究的治疗意向与方案分析

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2024-11-07 DOI:10.1038/s41408-024-01183-8

Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani

{"title":"CAR T 是一种药物还是一种治疗途径？复发难治弥漫大B细胞淋巴瘤CAR-T细胞疗法真实世界研究的治疗意向与方案分析","authors":"Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani","doi":"10.1038/s41408-024-01183-8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"243 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma\",\"authors\":\"Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani\",\"doi\":\"10.1038/s41408-024-01183-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"243 1\",\"pages\":\"\"},\"PeriodicalIF\":12.9000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-024-01183-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01183-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

$Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma$

查看原文本刊更多论文

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.